Previous Close | 4.28 |
1-Year Change | -72.14% |
6-Months Change | -24.65% |
3-Months Change | 5.16% |
Moving Avg (50d) | 4.797 |
Moving Avg (200d) | 4.9504 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 56.0M |
Beta (3-Years) | 0.71 |
Revenue Growth (ttm) | -5.38% |
Net Profit Margin (ttm) | 4.64% |
Return On Assets (ttm) | 2.95% |
EPS (ttm) | 0.91 |
PE Ratio (ttm) | 4.7 |
Dividend Yield | % |
Asset Description: | Eagle Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
4.194 | 4.066 | 3.98 | 3.852 | 3.638 | 3.424 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Pharmaceuticals |
Country: | United States |